ES2649438T3 - Derivados de benzo[1,3]dioxina y su uso como antagonistas de LPAR5 - Google Patents

Derivados de benzo[1,3]dioxina y su uso como antagonistas de LPAR5 Download PDF

Info

Publication number
ES2649438T3
ES2649438T3 ES13723767.3T ES13723767T ES2649438T3 ES 2649438 T3 ES2649438 T3 ES 2649438T3 ES 13723767 T ES13723767 T ES 13723767T ES 2649438 T3 ES2649438 T3 ES 2649438T3
Authority
ES
Spain
Prior art keywords
alkyl
dioxin
benzo
series consisting
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13723767.3T
Other languages
English (en)
Spanish (es)
Inventor
Marc Nazaré
Detlef Kozian
Martin Bossart
Werngard Czechtizky
Andreas Evers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Application granted granted Critical
Publication of ES2649438T3 publication Critical patent/ES2649438T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/081,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES13723767.3T 2012-05-18 2013-05-16 Derivados de benzo[1,3]dioxina y su uso como antagonistas de LPAR5 Active ES2649438T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305553 2012-05-18
EP12305553 2012-05-18
PCT/EP2013/060172 WO2013171318A1 (en) 2012-05-18 2013-05-16 Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists

Publications (1)

Publication Number Publication Date
ES2649438T3 true ES2649438T3 (es) 2018-01-12

Family

ID=48468297

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13723767.3T Active ES2649438T3 (es) 2012-05-18 2013-05-16 Derivados de benzo[1,3]dioxina y su uso como antagonistas de LPAR5

Country Status (16)

Country Link
US (1) US9221784B2 (enExample)
EP (1) EP2850070B1 (enExample)
JP (1) JP6238970B2 (enExample)
KR (1) KR20150016304A (enExample)
CN (1) CN104302633B (enExample)
AU (1) AU2013261719B2 (enExample)
BR (1) BR112014028189A2 (enExample)
CA (1) CA2871545A1 (enExample)
ES (1) ES2649438T3 (enExample)
IL (1) IL235219A (enExample)
MX (1) MX354521B (enExample)
PL (1) PL2850070T3 (enExample)
RU (1) RU2647727C2 (enExample)
SG (1) SG11201407216YA (enExample)
SI (1) SI2850070T1 (enExample)
WO (1) WO2013171318A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200215085A1 (en) * 2017-07-19 2020-07-09 Uti Limited Partnership Method to Abate Acute Airway Hypersensitivity and Asthma Attacks
KR20250140741A (ko) 2024-03-19 2025-09-26 경북대학교 산학협력단 알룰로스를 포함하는 혈전 예방 또는 개선용 조성물 및 이의 이용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056540A (en) 1974-01-01 1977-11-01 Bristol-Myers Company 4-Phenyl-1,3-benzodioxans
US4056450A (en) 1975-06-30 1977-11-01 M & T Chemicals Inc. Continuous detinning system
FR2424914A2 (fr) * 1978-05-03 1979-11-30 Roussel Uclaf Nouveaux derives de (1-3) benzodioxine, un procede pour leur preparation et leur application comme medicaments
SE445553B (sv) * 1978-05-03 1986-06-30 Roussel Uclaf /4h/-1,3-bensodioxan-2-karboxylsyraderivat
GB8310407D0 (en) * 1982-05-12 1983-05-25 Ici Plc 1 3 - dioxan -5- ylalkenoic acids
FR2704857B1 (fr) * 1993-05-07 1995-06-23 Adir Nouvelles benzodioxines substituées, leur procédé de préparation et les compositions pharmaceutiques les contenant.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
CN101124226A (zh) * 2004-05-07 2008-02-13 记忆药物公司 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途
WO2010042600A2 (en) * 2008-10-08 2010-04-15 The Uab Research Foundation Photo-activatable therapeutic agents and methods of using

Also Published As

Publication number Publication date
IL235219A (en) 2017-03-30
EP2850070B1 (en) 2017-08-23
KR20150016304A (ko) 2015-02-11
RU2014151240A (ru) 2016-07-10
BR112014028189A2 (pt) 2017-06-27
MX354521B (es) 2018-03-08
AU2013261719A1 (en) 2014-12-18
WO2013171318A1 (en) 2013-11-21
MX2014014012A (es) 2015-02-12
CN104302633B (zh) 2016-09-07
SI2850070T1 (en) 2018-01-31
CA2871545A1 (en) 2013-11-21
SG11201407216YA (en) 2014-12-30
PL2850070T3 (pl) 2018-01-31
JP2015517515A (ja) 2015-06-22
RU2647727C2 (ru) 2018-03-19
AU2013261719B2 (en) 2017-07-27
US20150111889A1 (en) 2015-04-23
CN104302633A (zh) 2015-01-21
EP2850070A1 (en) 2015-03-25
JP6238970B2 (ja) 2017-11-29
US9221784B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
KR102727059B1 (ko) 설포닐우레아와 관련 화합물 및 그 용도
US6060475A (en) Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof
BR112021011095B1 (pt) Compostos inibidores de il-17a de imidazo[1,2-b]piridazina, composição farmacêutica que os compreende e usos dos mesmos
JP2018115214A (ja) チエノピリミジン及びチエノピリジン化合物を含有する組成物並びにそれらの使用方法
KR101780140B1 (ko) Bace 억제제
AU2013255441B2 (en) Substituted pyrazole compounds as CRAC modulators
CA3036933A1 (en) Trpv4 antagonists
JP2016041726A (ja) 治療特性を有する1,4−ベンゾジアゼピン−2,5−ジオンおよび関連化合物
JP5856063B2 (ja) 治療特性を有する1,4−ベンゾジアゼピン−2,5−ジオンおよび関連化合物
WO2017060855A1 (en) Arylcyclohexyl pyrazoles as nrf2 regulators
Peng et al. Design, synthesis, and biological evaluation of 2-(phenoxyaryl)-3-urea derivatives as novel P2Y1 receptor antagonists
ES2649438T3 (es) Derivados de benzo[1,3]dioxina y su uso como antagonistas de LPAR5
JP2020500918A (ja) Nrf2レギュレーターとしてのn−アリールピラゾール
JP2021524469A (ja) Nrf2アクチベーターとしてのインダン
RU2547465C2 (ru) Соединение, обладающее ингибирующим действием в отношении фосфодиэстеразы 5 типа, и способ его получения
ES2346081T3 (es) Amidas de acido alcanoico sustituidas por o-heterociclos sustituidos.
CA2989982C (en) Imidazodiazepine compound
ES2321299T3 (es) Derivados de tiazol como antagonistas de npy.
TW202235408A (zh) 化合物
WO2019184744A1 (zh) 四氢异喹啉类衍生物及其制备方法和用途
BR112017017610B1 (pt) Composto de fórmula (ii) ou um sal ou solvato farmaceuticamente a c e i t á v e i s d o m e s m o , u s o d o c o m p o s t o o u d o s a l o u s o l v a t o farmaceuticamente aceitáveis e composição farmacêutica
HK1005801B (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists